Literature DB >> 16610707

CD95L/FasL and TRAIL in tumour surveillance and cancer therapy.

Harald Wajant1.   

Abstract

The membrane-bound death ligands CD95L/FasL and TRAIL, which activate the corresponding death receptors CD95/Fas, TRAILR1 and TRAILR2, induce apoptosis in many tumour cells, but can also elicit an inflammatory response. This chapter focuses on the relevance of CD95L/FasL and TRAIL for the tumour surveillance function of natural killer cells and cytotoxic T-cells and discuss current concepts of utilizing these ligands in tumour therapy.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16610707     DOI： 10.1007/0-387-26283-0_7

Source DB:  PubMed          Journal:  Cancer Treat Res        ISSN： 0927-3042


  27 in total

1.  CD4+VEGFR1(HIGH) T cell as a novel Treg subset regulates inflammatory bowel disease in lymphopenic mice.

Authors:  Jin-Young Shin; Il-Hee Yoon; Jong-Hyung Lim; Jun-Seop Shin; Hye-Young Nam; Yong-Hee Kim; Hyoung-Soo Cho; So-Hee Hong; Jung-Sik Kim; Won-Woo Lee; Chung-Gyu Park
Journal:  Cell Mol Immunol       Date:  2015-07-27       Impact factor: 11.530

2.  CD34+ gene expression profiling of individual children with very severe aplastic anemia indicates a pathogenic role of integrin receptors and the proapoptotic death ligand TRAIL.

Authors:  Ute Fischer; Christian Ruckert; Bernd Hubner; Olaf Eckermann; Vera Binder; Tamam Bakchoul; Friedhelm R Schuster; Sylvia Merk; Hans-Ulrich Klein; Monika Führer; Martin Dugas; Arndt Borkhardt
Journal:  Haematologica       Date:  2012-02-07       Impact factor: 9.941

3.  Protein kinase Cbeta modulates ligand-induced cell surface death receptor accumulation: a mechanistic basis for enzastaurin-death ligand synergy.

Authors:  Xue Wei Meng; Michael P Heldebrant; Karen S Flatten; David A Loegering; Haiming Dai; Paula A Schneider; Timothy S Gomez; Kevin L Peterson; Sergey A Trushin; Allan D Hess; B Douglas Smith; Judith E Karp; Daniel D Billadeau; Scott H Kaufmann
Journal:  J Biol Chem       Date:  2009-11-03       Impact factor: 5.157

4.  RIP1 modulates death receptor mediated apoptosis and autophagy in macrophages.

Authors:  Zhenyu Yao; Peng Zhang; Hui Guo; Juan Shi; Shilian Liu; Yanxin Liu; Dexian Zheng
Journal:  Mol Oncol       Date:  2014-12-30       Impact factor: 6.603

5.  Loss of Fas Expression and Function Is Coupled with Colon Cancer Resistance to Immune Checkpoint Inhibitor Immunotherapy.

Authors:  Wei Xiao; Mohammed L Ibrahim; Priscilla S Redd; John D Klement; Chunwan Lu; Dafeng Yang; Natasha M Savage; Kebin Liu
Journal:  Mol Cancer Res       Date:  2018-11-14       Impact factor: 5.852

6.  Restoration of tissue factor pathway inhibitor-2 in a human glioblastoma cell line triggers caspase-mediated pathway and apoptosis.

Authors:  Joseph George; Christopher S Gondi; Dzung H Dinh; Meena Gujrati; Jasti S Rao
Journal:  Clin Cancer Res       Date:  2007-06-15       Impact factor: 12.531

7.  Analysis of death receptor 5 and caspase-8 expression in primary and metastatic head and neck squamous cell carcinoma and their prognostic impact.

Authors:  Heath A Elrod; Songqing Fan; Susan Muller; Georgia Z Chen; Lin Pan; Mourad Tighiouart; Dong M Shin; Fadlo R Khuri; Shi-Yong Sun
Journal:  PLoS One       Date:  2010-08-16       Impact factor: 3.240

8.  Genistein induces receptor and mitochondrial pathways and increases apoptosis during BCL-2 knockdown in human malignant neuroblastoma SK-N-DZ cells.

Authors:  Joseph George; Naren L Banik; Swapan K Ray
Journal:  J Neurosci Res       Date:  2010-03       Impact factor: 4.164

9.  Tumorigenicity of IL-1alpha- and IL-1beta-deficient fibrosarcoma cells.

Authors:  Irina Nazarenko; Rachid Marhaba; Eli Reich; Elena Voronov; Mario Vitacolonna; Dagmar Hildebrand; Elena Elter; Mohini Rajasagi; Ron N Apte; Margot Zöller
Journal:  Neoplasia       Date:  2008-06       Impact factor: 5.715

Review 10.  Testing the theory of immune selection in cancers that break the rules of transplantation.

Authors:  Ariberto Fassati; N Avrion Mitchison
Journal:  Cancer Immunol Immunother       Date:  2009-12-22       Impact factor: 6.968
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.